cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Altimmune Inc
26 own
6 watching
Current Price
$15.04
$1.26
(9.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
739.39M
52-Week High
52-Week High
23.49
52-Week Low
52-Week Low
3.83
Average Volume
Average Volume
1.44M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization739.39M
icon52-Week High23.49
icon52-Week Low3.83
iconAverage Volume1.44M
iconDividend Yield--
iconP/E Ratio--
What does the Altimmune Inc do?
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Read More
How much money does Altimmune Inc make?
News & Events about Altimmune Inc.
Globe Newswire
30days ago
Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmentGAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business ...
Globe Newswire
30days ago
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the ...
Globe Newswire
2 months ago
GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual ...
Globe Newswire
3 months ago
GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago, ...
PR Newswire
3 months ago
Thinking about buying stock in Imara, Nutanix, Azul, 22nd Century Group, or Altimmune? Thinking about buying stock in Imara, Nutanix, Azul, 22nd Century Group, or Altimmune? PR Newswire NEW YORK, Oct. 14, 2022 NEW YORK, Oct. 14, 2022 /PRNewswire/ -- InvestorsObserverissues critical PriceWatch...
Frequently Asked Questions
Frequently Asked Questions
What is Altimmune Inc share price today?
plus_minus_icon
Can Indians buy Altimmune Inc shares?
plus_minus_icon
How can I buy Altimmune Inc shares from India?
plus_minus_icon
Can Fractional shares of Altimmune Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Altimmune Inc stocks?
plus_minus_icon
What is today’s traded volume of Altimmune Inc?
plus_minus_icon
What is today’s market capitalisation of Altimmune Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Altimmune Inc?
plus_minus_icon
What percentage is Altimmune Inc down from its 52-Week High?
plus_minus_icon
What percentage is Altimmune Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$15.04
$1.26
(9.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$12.93
$0.31 (2.46 %)
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
$28.45
$-0.49 (-1.69 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$23.05
$1.57 (7.31 %)
Provention Bio Inc
Provention Bio Inc
$9.10
$0.51 (5.94 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$12.93
$0.31 (2.46 %)
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
$28.45
$-0.49 (-1.69 %)
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
$23.05
$1.57 (7.31 %)
Provention Bio Inc
Provention Bio Inc
$9.10
$0.51 (5.94 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00